Literature DB >> 32926225

Online interest in surgical treatment for benign prostatic hyperplasia using Google trends.

Samir Merheb1, Na Wang2, Janice Weinberg3, David S Wang1, Shaun E L Wason4.   

Abstract

PURPOSE: Online health information-seeking behavior has increased over the past 15 years; however, little is known about the online interest for surgical treatment of men with benign prostatic hyperplasia. We used Google Trends to evaluate online interest for various surgical procedures for benign prostatic hyperplasia in the US and worldwide.
METHODS: Transurethral resection of the prostate, photoselective vaporization of the prostate, Holmium laser enucleation of the prostate, Urolift, and Rezum were selected as search terms of interest within Google Trends. Google Trends normalizes the popularity of search terms on a 0-100 scale. ANOVA and the average rate of change in popularity scores were conducted from July 2015 to February 2019.
RESULTS: From 2004 to 2019, online interest in transurethral resection of the prostate and photoselective vaporization of the prostate remained stable in the US and worldwide; meanwhile, there was an upward trend for Urolift and Rezum. There was a statistically significant increase in the online interest for Holmium laser enucleation of the prostate in the US and worldwide; however, the mean popularity score was significantly higher worldwide.
CONCLUSIONS: A shift in online interest towards minimally invasive surgical therapies for benign prostatic hyperplasia was demonstrated in the US and worldwide and parallels clinical practice patterns, such as HoLEP and Urolift surgical volumes in Indiana and Australia, respectively. Google Trends can be used in real-time to gauge online interest for surgical procedures and help guide physician-patient counseling.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Benign prostatic hyperplasia; Google trends; Rezum; TURP; Urolift

Mesh:

Year:  2020        PMID: 32926225     DOI: 10.1007/s00345-020-03445-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  15 in total

Review 1.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

2.  Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift.

Authors:  Kevin T McVary; Steven N Gange; Neal D Shore; Damien M Bolton; Barrett E Cowan; B Thomas Brown; Alexis E Te; Peter T Chin; Daniel B Rukstalis; Claus G Roehrborn
Journal:  J Sex Med       Date:  2013-09-30       Impact factor: 3.802

3.  Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study.

Authors:  Christian Gratzke; Neil Barber; Mark J Speakman; Richard Berges; Ulrich Wetterauer; Damien Greene; Karl-Dietrich Sievert; Christopher R Chapple; Jacob M Patterson; Lasse Fahrenkrug; Martin Schoenthaler; Jens Sonksen
Journal:  BJU Int       Date:  2016-12-21       Impact factor: 5.588

4.  Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.

Authors:  Claus G Roehrborn; Steven N Gange; Marc C Gittelman; Kenneth A Goldberg; Kalpesh Patel; Neal D Shore; Richard M Levin; Michael Rousseau; J Randolf Beahrs; Jed Kaminetsky; Barrett E Cowan; Christopher H Cantrill; Lance A Mynderse; James C Ulchaker; Thayne R Larson; Christopher M Dixon; Kevin T McVary
Journal:  J Urol       Date:  2016-12-18       Impact factor: 7.450

5.  Use of Google Trends to Track Online Behavior and Interest in Kidney Stone Surgery.

Authors:  Paulette Cutruzzula Dreher; Carmen Tong; Eric Ghiraldi; Justin I Friedlander
Journal:  Urology       Date:  2018-08-01       Impact factor: 2.649

6.  A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.

Authors:  James A Thomas; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; Alexander Bachmann
Journal:  Eur Urol       Date:  2015-08-15       Impact factor: 20.096

7.  Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline.

Authors:  Harris E Foster; Michael J Barry; Philipp Dahm; Manhar C Gandhi; Steven A Kaplan; Tobias S Kohler; Lori B Lerner; Deborah J Lightner; J Kellogg Parsons; Claus G Roehrborn; Charles Welliver; Timothy J Wilt; Kevin T McVary
Journal:  J Urol       Date:  2018-06-11       Impact factor: 7.450

8.  Health Information Obtained From the Internet and Changes in Medical Decision Making: Questionnaire Development and Cross-Sectional Survey.

Authors:  Yen-Yuan Chen; Chia-Ming Li; Jyh-Chong Liang; Chin-Chung Tsai
Journal:  J Med Internet Res       Date:  2018-02-12       Impact factor: 5.428

9.  Consulting "Dr. Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis.

Authors:  Giovanni E Cacciamani; Silvia Bassi; Marco Sebben; Anna Marcer; Giorgio I Russo; Andrea Cocci; Paolo Dell'Oglio; Luis G Medina; Nima Nassiri; Alessandro Tafuri; Andre Abreu; Antonio B Porcaro; Alberto Briganti; Francesco Montorsi; Inderbir S Gill; Walter Artibani
Journal:  Eur Urol Oncol       Date:  2019-07-31

10.  Information from the Internet and the doctor-patient relationship: the patient perspective--a qualitative study.

Authors:  Fiona A Stevenson; Cicely Kerr; Elizabeth Murray; Irwin Nazareth
Journal:  BMC Fam Pract       Date:  2007-08-16       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.